通常以血浆生长激素(GH)浓度判断肢端肥大症的疗效。但GH促进生长的作用需有生长激素介质(Somatomedinsi SM)参与。为了解生长激素介质-C(SM—C)在判断疾病的活动性和疗效方面是否优于GH,作者对31名用溴隐亭治疗的肢端肥大症患者进行了观察。31名全为临床活动性患者(即口服75克葡萄糖后,血浆GH均不能被抑制至4mu/L以下)。溴隐亭 The efficacy of acromegaly is usually judged by the concentration of plasma growth hormone (GH). However, the role of GH in promoting growth requires the involvement of Somatomedinsi SM. To understand if growth hormone mediator C (SM-C) is superior to GH in determining disease activity and efficacy, 31 patients with acromegaly treated with bromocriptine were observed. Thirty-one patients were all clinically active (ie, 75 g of glucose orally, the plasma GH can not be suppressed to 4mu / L or less). Bromocriptine